Phase 2 N=50 Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19
COVID-19
Primary: Time to Viral Clearance — 16.0; 30.0 days — p=0.0415
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 Reoxygenation After Cardiac Arrest II (REOX II Study)
Cardiac Arrest
Primary: Plasma Isofurans (pg/mL)/Isoprostanes (pg/mL) Ratio
N/A N=24 On-Track Feasibility Study of a Rehabilitation System for Stroke Patients
Cerebrovascular Accident
Primary: Number of Participants Finding the OnTrack Intervention Acceptable in Semi Structured Interviews — 12 Participants
N/A N=428 Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Progression Free Survival — 8.0; 7.2 Months — p=0.0013
Phase 2 N=29 Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients
Cancer of Prostate
Primary: Biochemical Response Rate Based on PSA — 3; 5 Participants
N/A N=6 Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial
Spasmodic Dysphonia · Laryngeal Dystonia · Deep Brain Stimulation
Primary: Unified Spasmodic Dysphonia Rating Scale (USDRS) — 2.5; 3.75 units on a scale — p=0.025
Phase 2 N=110 A Study of Acetaminophen for Post Surgical Dental Pain
Pain, Postoperative · Dental Pain
Primary: Sum of Pain Intensity Difference From 0 to 24 Hours (SPID24) Based on the 11 Point Numeric Pain Rating Scale — -96.80; -100.69; -74.96 score on a scale — p=0.0258
Early Phase 1 N=49 Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis
Uveitis
Primary: Change in Mean Number of Uveitis Relapses Per Patient Between the 12 Month Study Period Compared to Baseline — 0.35; 0.58 Relapses Per Patient
N/A N=5 Recovery of Cardiovascular Function With Epidural Stimulation After Human Spinal Cord Injury
Spinal Cord Injury
Primary: Mean Arterial Blood Pressure in Response to Epidural Stimulation — 112.5 mmHg
Phase 1 N=170 Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
Blood Donors
Primary: Red Blood Cell Post-filtration Recovery — 92.57; 92.70; 90.96; 90.23 % recovery at day 0
Phase 3 N=112 Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure
Thrombosis
Primary: Percentage of Participants With Any Thrombotic Event (Venous or Arterial and Symptomatic or Asymptomatic) — 8.3; 1.6; 8.8; 0 percentage of participants
Phase 3 N=912 A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
Atopic Dermatitis
Primary: Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 — 13.3; 60.1; 72.9…
Phase 3 N=169 Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
Vernal Keratoconjunctivitis
Primary: Average Penalties Adjusted Composite Efficacy Score (CFS) Score Over the 4 Months — 2.06; 1.93; 1.34 Penalties Adjusted CFS Score — p=0.007
Phase 3 N=930 Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder
Insomnia Disorder
Primary: Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance) — -18.40; -28.98; -6.20 minutes — p=<0.0001
Phase 4 N=51 Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML
ECG · Pharmacokinetics · Safety
Primary: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF) at Cycle 1 Day 1: 1 Hour — 4.90 milliseconds